复发分化型甲状腺癌中[18F]四氟硼酸盐PET-CT相较于[131I]碘闪烁显像的增量诊断价值
本回顾性分析纳入25例复发分化型甲状腺癌患者,比较[18F]TFB-PET与临床参考标准[131I]碘显像的诊断效能。[18F]TFB-PET在显著更多患者中检出复发或转移(13/25=52% vs 3/25=12%,p=0.002),[18F]TFB-PET联合[18F]FDG-PET-CT灵敏度最高(64%)。
要点
- [18F]TFB-PET检出复发或转移的患者数显著多于[131I]碘显像(52% vs 12%,p=0.002)。
- 6例颈部淋巴结转移患者经[18F]TFB-PET显示hNIS表达而重新分类为部分去分化。
- [18F]TFB-PET-CT/MRI联合[18F]FDG-PET-CT的灵敏度最高(64%)。
核心结论
- 在本队列中,[18F]TFB-PET检测复发分化型甲状腺癌的灵敏度和准确性高于[131I]碘全身显像及SPECT-CT。
- [18F]TFB-PET联合[18F]FDG-PET-CT似乎是表征分化型甲状腺癌病灶分化程度、并据此个体化制定和监测治疗方案的合理策略。
- 作者认为需要未来前瞻性研究评估[18F]TFB-PET在复发分化型甲状腺癌中的潜力。
研究设计与样本
- 回顾性分析纳入25例复发分化型甲状腺癌患者。
- 所有患者因新发现甲状腺球蛋白升高、抗甲状腺球蛋白升高、超声可疑颈部淋巴结或上述组合而接受[18F]TFB-PET联合CT或MRI检查。
- 所有患者均有配对的[131I]碘全身显像(dxWBS)包括SPECT-CT,21例有配对的[18F]FDG-PET-CT。
- 4例患者有[18F]TFB阳性发现的组织学验证。
主要发现
- [18F]TFB-PET检出局部复发或转移的患者数显著多于常规[131I]碘dxWBS及SPECT-CT(13/25=52% vs 3/25=12%,p=0.002)。
- 6例颈部淋巴结转移患者FDG代谢轻度增高但[131I]碘显像阴性,[18F]TFB-PET显示转移灶hNIS表达,因而重新分类为仅部分去分化(其中2例有组织学确认)。
- 检测复发分化型甲状腺癌灵敏度最高的是[18F]TFB-PET-CT/MRI联合[18F]FDG-PET-CT(64%)。
临床怎么用
- 作者认为[18F]TFB-PET联合[18F]FDG-PET-CT似乎是表征分化型甲状腺癌病灶分化程度并据此个体化制定和监测治疗方案的合理策略。
局限性
- 本文为回顾性分析。
- 仅4例患者有[18F]TFB阳性发现的组织学验证。
- 作者认为需要未来前瞻性研究评估[18F]TFB-PET在复发分化型甲状腺癌中的潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Efficient therapy of recurrent differentiated thyroid cancer (DTC) is dependent on precise molecular imaging techniques targeting the human sodium iodide symporter (hNIS), which is a marker both of thyroid and DTC cells. Various iodine isotopes have been utilized for detecting DTC; however, these come with unfavorable radiation exposure and image quality ([131I]iodine) or limited availability ([124I]iodine). In contrast, [18F]tetrafluoroborate (TFB) is a novel radiolabeled PET substrate of hNIS, results in PET images with high-quality and low radiation doses, and should therefore be suited for imaging of DTC. The aim of the present study was to compare the diagnostic performance of [18F]TFB-PET to the clinical reference standard [131I]iodine scintigraphy in patients with recurrent DTC. METHODS: Twenty-five patients with recurrent DTC were included in this retrospective analysis. All patients underwent [18F]TFB-PET combined with either CT or MRI due to newly discovered elevated TG levels, antiTG levels, sonographically suspicious cervical lymph nodes, or combinations of these findings. Correlative [131I]iodine whole-body scintigraphy (dxWBS) including SPECT-CT was present for all patients; correlative [18F]FDG-PET-CT was present for 21 patients. Histological verification of [18F]TFB positive findings was available in 4 patients. RESULTS: [18F]TFB-PET detected local recurrence or metastases of DTC in significantly more patients than conventional [131I]iodine dxWBS and SPECT-CT (13/25 = 52% vs. 3/25 = 12%, p = 0.002). The diagnosis of 6 patients with cervical lymph node metastases that showed mildly increased FDG metabolism but negative [131I]iodine scintigraphy was changed: [18F]TFB-PET revealed hNIS expression in the metastases, which were therefore reclassified as only partly de-differentiated (histological confirmation present in two patients). Highest sensitivity for detecting recurrent DTC had the combination of [18F]TFB-PET-CT/MRI with [18F]FDG-PET-CT (64%). CONCLUSION: In the present cohort, [18F]TFB-PET shows higher sensitivity and accuracy than [131I]iodine WBS and SPECT-CT in detecting recurrent DTC. The combination of [18F]TFB-PET with [18F]FDG-PET-CT seems a reasonable strategy to characterize DTC tumor manifestations with respect to their differentiation and thereby also individually plan and monitor treatment. Future prospective studies evaluating the potential of [18F]TFB-PET in recurrent DTC are warranted.
引用
- Dittmann M, Gonzalez Carvalho JM, Rahbar K, et al. Incremental diagnostic value of [18F]tetrafluoroborate PET-CT compared to [131I]iodine scintigraphy in recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32248325. doi:10.1007/s00259-020-04727-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。